KLDO - Kaleido Biosciences to delist from Nasdaq as business operations end

On Friday, the clinical-stage healthcare company Kaleido Biosciences (NASDAQ:KLDO) announced that it would voluntarily delist its shares in the Nasdaq Global Select Stock Market following a decision to immediately discontinue its business operations. The company plans to submit a regulatory filing in this regard to the Securities and Exchange Commission (SEC) within the next few days. A formal notice has been issued to the Nasdaq Stock Market on April 08, and delisting is expected to take effect on or about April 28. The plans on delisting followed a vote taken by the company’s board on Friday to immediately wind down and cease all of the operations, Kaleido (KLDO) said, adding that a previously announced strategic process to maximize shareholder value did not lead to viable deals. “….given its limited remaining resources, the Company cannot continue operations and believes that the best alternative is an orderly wind-down process,” (KLDO) said in a

For further details see:

Kaleido Biosciences to delist from Nasdaq as business operations end